Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
Conference Series LLC has designed global platforms to interact and collaborate with renowned speakers, experts and industry professionals at its 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on diverse Medical, Pharma, Engineering, Science, Technology and Business field. Hematology conferences organized by Conference Series LLC focuses on all types of blood disorders. From past 4 years, it has already emerged to be an excellent informative program which showcases recent advancement in this research field in terms of the improved diagnosis and treatment protocols.
Hematology or haematology is the study which emphasizes on the diagnosis, treatment, and prevention of diseases related to the blood, blood-forming organs and blood diseases. The word "heme" comes from the Greek for blood. Hematology is practiced by specialists in the field who deal with the diagnosis, treatment and overall management of people with blood disorders ranging from anemia to blood cancer. Blood, which is essential for life, is composed of different types of cells with specific functions — red blood cells transport oxygen through the body, white blood cells defends against infection and platelets help control bleeding. These cells are made in bone marrow, so well-functioning bone marrow is necessary for healthy blood. It carries essential nutrients to tissues throughout the body. Abnormalities in the number of cells in the blood can produce several conditions. There are many types of blood disorders, which can involve problems with red blood cells, white blood cells, platelets, blood vessels, bone marrow, lymph nodes, or the proteins involved in bleeding and clotting. The medical aspect of hematology is concerned with the treatment of blood disorders and malignancies, including types of hemophilia, leukemia, lymphoma and sickle-cell anemia. Hematology is a branch of internal medicine that deals with the physiology, pathology, etiology, diagnosis, treatment, prognosis and prevention of blood-related disorders.
Hematologist is the physician who specializes in diagnosing and treating diseases of the blood. Hematologist works in a variety of environments, including blood banks, pathology laboratories and private clinics. Specialists in this branch of medicine also choose to focus on specific topics within the field of hematology, such as lymphatic organs and bone marrow and may diagnose blood count irregularities or platelet irregularities.
Importance and Scope
Over the past few decades, hematology research innovations have resulted in significant improvements in care for patients with blood disorders. Despite this immense and remarkable progress in understanding and treating of hematologic diseases, substantial challenges are still there, hence there is huge scope, importance as well as requirement of hematology research, which will eventually improve the quality of life with better treatment and diagnosis options.
An average about 15% of world’s population is affected by different types of blood disorders. A major part of research is going on at the top Universities across the globe, on Thrombosis and Hematology and the grants allotted for this research field is around $ 750 million. The global hematology market has been segmented into commercial organizations, stand-alone hospitals, research institutes, and clinical testing labs.
According to market study, the market of hematology is expressed to show steady growth rate during the forecast period from 2014 – 2020. This growth is driven by major factors, such as rising prevalence of various diseases and extensive R&D practices are on-going across the globe to bring new and more effective drugs and formulations in the market. Further, due to extensive R&D practices, a number of drugs and formulations are under pipeline studies. New therapy and drugs such as, histone deacetylase (HDAC) inhibitors, immunomodulatory drugs and proteasome inhibitors are under pipeline study and expected to enter in the market during forecast period. These drivers are anticipated to accentuate the growth of the market.
The total global market for hematological disorder drugs and diagnostics in 2012 was estimated at nearly $72.9 billion. By 2017, the market is expected to reach $99.1 billion, growing at a compound annual growth rate (CAGR) of 6.4% between 2012 and 2017. The global blood disorders market segment is estimated at $49.3 billion in 2012 and is expected to reach nearly $64.7 billion by 2017. The major reason for the low growth rate is the expected decline in the annual cost of treating blood disorders and the patent expirations of Lovenox, Plavix, Procrit/Epogen, Aranesp, and Neulasta. In 2010, all these drugs together brought revenue of about $32 billion into the global blood disorders market.) The global market for haematological cancer drugs was estimated to be $18.7 billion in 2012. By 2017, the market is expected to reach $28.8 billion, growing at a CAGR of 9% between 2012 and 2017.
The North American region is the most dominating market in the world, owing to rapidly growing incidences of lymphoma cancers and rising focus towards R&D for hematological malignancies treatments. For instance, Lymphoma Research Foundation stated that, T-cell lymphomas accounted for approximately 15% of all non-Hodgkin lymphomas in the U.S. every year. On the other hand, Asia-Pacific and RoW region are the most promising markets in the upcoming period, owing to rise in awareness of blood cancers and its chronic impacts along with its treatments. The Research market research report will increase the awareness of current and emerging drugs and technologies for hematological disorders and blood cancers, including hematological disorder therapeutics, chemotherapy, radiation therapy, surgical therapy, immunotherapy, and nutrition therapy. Novartis International AG, GlaxoSmithKline Pharmaceuticals Limited, Roche, Bristol-Myers Squibb, Genmab A/S, Celgene Corporation, and Biogen Idec rule the present market for leukaemia drugs; whereas Ambit Bioscience & Pfizer are expected to capture major share of the market by 2020.